Trump Signs Executive Order Reclassifying Cannabis to Schedule III, Opening New Pathways for Medical Research
核心洞察
President Trump signed an executive order downgrading cannabis from Schedule I to Schedule III, removing decades-old regulatory hurdles that have prevented FDA research into medical cannabis and CBD.
The reclassification will make it far easier for researchers to obtain funding for clinical trials and for pharmaceutical companies to apply for FDA approval of marijuana-derived medications.
Dr. Nora Volkow from NIDA (搜索) emphasized that the reschedule opens the door to accelerate research and discovery, particularly for patients who report cannabis can solve their medical problems.
President Donald Trump on Thursday signed an executive order downgrading cannabis from a Schedule I substance to Schedule III, removing decades-old regulatory barriers that have prevented comprehensive medical research into its therapeutic potential. The reclassification moves cannabis from the same category as heroin, LSD and ecstasy to a classification that includes controlled substances such as codeine, morphine, and certain stimulants.
Speaking from the Oval Office, Trump described the move as common sense policy, stating that the reclassification will allow the Food and Drug Administration (FDA) to research medical cannabis and cannabidiol (CBD) as potential alternatives to opioid painkillers. "This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments," Trump said during the press briefing.
Accelerating Research and Discovery
The executive order, titled "Increasing Medical Marijuana and Cannabidiol Research," directs Attorney General Pam Bondi to finalize the rescheduling process that began under the Biden administration in December 2024. The change removes regulatory hurdles that have largely kept drug companies from conducting the clinical trials necessary for regulatory approval of new marijuana-derived drugs.
Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA (搜索)), emphasized the research implications at the press briefing. "The reschedule opens the door to actually be able to accelerate the rate at which we can do research and discovery," Volkow said. "Yes, cannabis can be addictive … but we cannot close our eyes to research and the opportunity that we are hearing from patients that, for some of them, cannabis can solve their problem."
The reclassification will make it easier for researchers to obtain funding for clinical trials and for pharmaceutical companies to apply for FDA approval. As a Schedule I substance, bureaucratic and financial hurdles have prevented comprehensive research into cannabis-derived medications.
Current Therapeutic Landscape
Currently, only three cannabinoid drugs have demonstrated evidence from clinical trials necessary for FDA approval. Epidiolex from Jazz Pharmaceuticals, containing purified CBD derived from hemp, is approved for certain seizure disorders (搜索). Dronabinol, a synthetic form of THC sold as Marinol by Alkem Laboratories and Syndros by Benuvia (搜索), is approved for loss of appetite in people with HIV/AIDS (搜索) and for nausea and vomiting due to chemotherapy.
Several experimental treatments are showing promise in clinical trials. An experimental cannabis-derived medication from Vertanical (搜索) demonstrated superior safety and efficacy compared to placebo and opioids for treating chronic lower back pain (搜索) in two late-stage trials in Europe, with a U.S. trial planned for 2026. Sativex from CNX Therapeutics (搜索), an oral spray formulation, has shown efficacy in late-stage trials for managing muscle spasticity in people with multiple sclerosis (搜索) and is approved in over 30 countries outside the United States.
Regulatory Framework and Safety Considerations
Trump emphasized that the federal order "doesn't legalize marijuana in any way, shape or form," nor does it "sanction use as a recreational drug." Manufacture, distribution, and possession of marijuana without legal authorization would continue to be unlawful, but penalties would likely be less severe than those tied to its current Schedule I status.
Cannabis contains chemical compounds known as cannabinoids that interact with chemical systems in the body. The two best-known cannabinoids are tetrahydrocannabinol (THC), which causes a euphoric high, and cannabidiol (CBD), which produces physiological effects such as potential pain or inflammation relief without the high.
Even when used for medical reasons, cannabinoid products can cause dizziness and gastrointestinal symptoms and can impact cognitive status, mental health, the cardiovascular system, and the lungs. Recent data has also linked marijuana use with a higher risk for developing type 2 diabetes (搜索). Marijuana interacts with many prescription and over-the-counter medications, including blood thinners, sleep medications, anxiety medications, antidepressants, and seizure medications.
Future Research Directions
Cannabinoid drugs are currently being tested for treatment of autism spectrum disorder (搜索), anxiety and depression in bipolar disorder (搜索), endometriosis (搜索), eczema and alcohol use disorder. Federal rescheduling of cannabis is expected to accelerate research and standardized drug development for these and other conditions.
Any drugs that are eventually approved by the FDA would be legally available in commercial pharmacies by prescription. Healthcare providers who wish to prescribe Schedule III medications, including any marijuana-derived drugs, must have a valid Drug Enforcement Administration registration.
The reclassification represents a significant shift in federal cannabis policy, potentially opening new therapeutic avenues while maintaining regulatory oversight and safety standards for medical research and development.